Sugi Predict

Sugi Predict / Compounds / SCHEMBL474280

SCHEMBL474280

SCHEMBL474280

Nc1nc(-c2cc(Cl)cc(C(F)(F)F)c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPL P40238 3/20 0.52
▸ LTA4H P09960 4/20 0.51
▸ ADORA2A P29274 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ RORB Q92753 2/20 0.47
▸ ALOX5 P09917 3/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ RORC P51449 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ NFKB1 P19838 2/20 0.41
▸ NFKB2 Q00653 2/20 0.41
▸ RELA Q04206 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ AR P10275 1/20 0.41
▸ GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278201 0.89 LTA4H (0.58) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL476082 0.83 LTA4H (0.56) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL474188 0.83 MAPT (0.55) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL29654146 0.81 LTA4H (0.51) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL17407196 0.81 LTA4H (0.55) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL18724009 0.81 ALDH1A1 (0.54) MPLLTA4HRORBALOX5ALDH1A1
Bromide SCHEMBL8360770 0.81 MAPT (0.54) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL18724007 0.81 LTA4H (0.51) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL2762616 0.81 MPL (0.51) MPLLTA4HALOX5ALDH1A1RAB9A
SCHEMBL21301111 0.80 NPC1 (0.56) ADORA2AADORA1RORBALOX5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49111-E1 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2022-06-21 — — US disclosed
EP-3153511-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES ASTELLAS PHARMA INC (JP) 2019-05-15 — — EP disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 — — US disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 — — US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 — — US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 — — US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 — — US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 — — US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 — — US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 — — US disclosed
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-01-12 — — US disclosed
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-01-12 — — US disclosed
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-01-12 — — US disclosed
WO-2011132017-A1 PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2011-10-27 — — WO disclosed
WO-2010125469-A1 PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-04 — — WO disclosed
WO-2010125469-A1 PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-04 — — WO disclosed
WO-2010109328-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010109328-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 MPL 2992/4885LTA4H 423/4885ADORA2A 67/4885
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 MPL 3647/4885LTA4H 1000/4885ADORA2A 161/4885
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 MPL 3786/4885LTA4H 850/4885ADORA2A 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.